



BSI Standards Publication

Biotechnology — Analytical methods — General requirements and considerations for the testing and characterization of cellular therapeutic products

This is a preview of "BS ISO 23033:2021". [Click here to purchase the full version from the ANSI store.](#)

National foreword

This British Standard is the UK implementation of ISO 23033:2021.

The UK participation in its preparation was entrusted to Technical Committee BTI/1, Biotechnologies.

A list of organizations represented on this committee can be obtained on request to its committee manager.

Contractual and legal considerations

This publication has been prepared in good faith, however no representation, warranty, assurance or undertaking (express or implied) is or will be made, and no responsibility or liability is or will be accepted by BSI in relation to the adequacy, accuracy, completeness or reasonableness of this publication. All and any such responsibility and liability is expressly disclaimed to the full extent permitted by the law.

This publication is provided as is, and is to be used at the recipient's own risk.

The recipient is advised to consider seeking professional guidance with respect to its use of this publication.

This publication is not intended to constitute a contract. Users are responsible for its correct application.

© The British Standards Institution 2021
Published by BSI Standards Limited 2021

ISBN 978 0 580 52192 8

ICS 07.080

Compliance with a British Standard cannot confer immunity from legal obligations.

This British Standard was published under the authority of the Standards Policy and Strategy Committee on 31 October 2021.

Amendments/corrigenda issued since publication

Date	Text affected
------	---------------

This is a preview of "BS ISO 23033:2021". [Click here to purchase the full version from the ANSI store.](#)

First edition
2021-08-27

Biotechnology — Analytical methods — General requirements and considerations for the testing and characterization of cellular therapeutic products

*Biotechnologie — Méthodes analytiques — Exigences et
considérations générales pour les essais et la caractérisation de
produits de thérapie cellulaire*



Reference number
ISO 23033:2021(E)

© ISO 2021

This is a preview of "BS ISO 23033:2021". [Click here to purchase the full version from the ANSI store.](#)



COPYRIGHT PROTECTED DOCUMENT

© ISO 2021, Published in Switzerland

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
Ch. de Blandonnet 8 • CP 401
CH-1214 Vernier, Geneva, Switzerland
Tel. +41 22 749 01 11
Fax +41 22 749 09 47
copyright@iso.org
www.iso.org

This is a preview of "BS ISO 23033:2021". [Click here to purchase the full version from the ANSI store.](#)

Contents

Page

Foreword	v
Introduction	vi
1 Scope	1
2 Normative references	1
3 Terms and definitions	1
4 Cellular starting materials	8
5 Design of fit for purpose analytical methods for evaluating quality attributes	9
5.1 General concepts	9
5.2 Approach to analytical method design	11
5.3 Defining quality attributes by considering components of a cellular therapeutic product	11
5.4 Design of a matrix of analytical methods	14
5.5 Design of a fit for purpose analytical method	14
5.6 Selection of instruments	15
5.7 Instrument qualification and maintenance	16
5.8 Managing sources of measurement variability for cell measurements	17
5.8.1 General	17
5.8.2 Sampling and sample preparation	18
5.8.3 Reference materials	19
5.8.4 Analytical reagents	19
5.9 Documentation of procedure	20
6 Analytical method qualification, validation and continued verification	20
6.1 General	20
6.2 Analytical method qualification	20
6.3 Analytical method validation and continued verification	21
6.3.1 Validation	21
6.3.2 Continued verification	23
6.4 Test method performance criteria	23
7 Testing of cellular therapeutic products	24
7.1 Considerations for specifications and release criteria for cellular therapeutic products	24
7.1.1 General	24
7.1.2 Considerations for release criteria for the final cellular therapeutic product	24
7.2 General requirements for the testing of the cellular therapeutic product	24
7.3 Testing to evaluate identity of a cellular therapeutic product	25
7.4 Testing to evaluate cell counts within cellular therapeutic products	26
7.5 Testing to evaluate viability of cells within a cellular therapeutic product	26
7.6 Testing to evaluate potency of a cellular therapeutic product	26
7.6.1 General	26
7.6.2 Importance of potency as a CQA	27
7.6.3 Assessment of potency	27
7.6.4 Requirements for analytical methods that evaluate potency	27
7.6.5 Design of analytical methods that evaluate potency	28
7.6.6 Considerations for analytical methods that evaluate potency	28
7.7 Testing to evaluate the purity of cellular therapeutic products	28
7.8 Testing to evaluate microbiological contamination of cellular therapeutic products	29
7.9 Testing to evaluate stability of cellular therapeutic products	30
8 Reporting	31
8.1 General	31
8.2 General requirements	31
Annex A (informative) Establishing a testing strategy for cellular therapeutic products	32

This is a preview of "BS ISO 23033:2021". [Click here to purchase the full version from the ANSI store.](#)

Annex B (informative) Examples of potential sources of variability in a cell analytical method	33
Bibliography	34

This is a preview of "BS ISO 23033:2021". [Click here to purchase the full version from the ANSI store.](#)

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 276, *Biotechnology*.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Introduction

The emergence of cellular therapeutic products has increased the need for high quality, robust, and validated measurements for the characterization and testing of products containing cells as the active substance. These products are regulated by regional health authorities who evaluate product quality in terms of their quality attributes (QAs) via appropriate biological, physical and chemical assays (analytical methods).

Analytical methods are performed on cellular starting materials, in in-process testing and as a part of product conformance testing, comparability studies, and stability testing. These analytical methods are used to assess attributes associated with product quality features and manufacturing controls (in-process controls), and are performed to establish identity, purity, cell count, viability, potency, and stability in all phases of clinical study and commercialization. Quality attributes are used to ensure that only product lots that meet defined specifications are released. Quality attributes are also used for stability testing and trending purposes as well as in-process indicators.

Analytical methods also underpin the development of new cellular therapeutic products by providing insight into biological mechanisms of action and facilitating the research and development that advances manufacturing. In addition, analytical methods are used to evaluate and compare cellular therapeutic products from different batches that have, for example, been produced on different days, at different locations, or via a changed manufacturing process.

Quantitative measurement of a cellular therapeutic product is challenging due to the complex and highly dynamic nature of viable cells and cell samples, the varying vulnerability of cell types and processing steps, a lack of understanding of fundamental cell biology, and the large number of parameters associated with bioprocessing and measurement processes. Biological variability further complicates measurements. Additionally, different donor samples can have different susceptibilities to processing steps, making the need for in-process controls during the measurement process even more critical. As such, analytical methods are key to evaluate cellular therapeutic products, as well as the cellular starting material and intermediate, although the specific performance criteria can be different from those of the final cellular therapeutic products.

This document provides a general approach to design fit for purpose analytical methods to measure and assess quality attributes of a cellular therapeutic product. Aspects of this document can also be applicable to the testing and characterization of cells used in viruses, exosome, and antibody production. The general process to select and design fit for purpose analytical methods can be applied to cellular starting material, intermediates, cell end products, control cells, feeder cells, and cells used in assays (e.g. target cells). It also provides general approaches to understand, minimize, and monitor sources of variability. Acceptable levels of accuracy and precision are guided by the biological implications of the measurement result and the practical limitations of the measurement process.

This document also provides general considerations for setting specifications for the testing of a final cellular therapeutic product. General considerations are also provided for establishing analytical methods and analytical strategies (including analytical method matrix approaches) for common categories of critical quality attributes (CQAs) (i.e. attributes used to establish identity, cell count, purity or impurity, potency or relevant biological activity, viability, sterility, stability, and maturation profile).

This document was developed to provide additional technical guidance on cell characterization and specifically outlines approaches for strategic development of analytical methods cellular therapeutic product characterization and testing (see [Annex A](#) for schematic outline of concepts presented in this document).

This is a preview of "BS ISO 23033:2021". Click here to purchase the full version from the ANSI store.

Biotechnology — Analytical methods — General requirements and considerations for the testing and characterization of cellular therapeutic products

1 Scope

This document provides general requirements for the testing of cellular therapeutic products intended for human use.

This document also provides considerations for the characterization of cellular therapeutic products, including approaches to select and design analytical methods that are fit for purpose.

Such considerations can be used to establish critical quality attributes for a cellular therapeutic product.

This document is applicable to cellular starting materials (including those for tissue engineered products) and intermediates of cellular therapeutic products.

This document is not applicable to tissues used in transplantation.

2 Normative references

There are no normative references in this document.

3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

ISO and IEC maintain terminology databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at <https://www.iso.org/obp>
- IEC Electropedia: available at <http://www.electropedia.org/>

3.1

acceptance criteria

numerical limits, ranges, or other suitable measures for acceptance of the results of analytical procedures which the product or materials at other stages of manufacture is intended to meet

3.2

adventitious agent

microorganisms unintentionally introduced into the manufacturing process

Note 1 to entry: Microorganisms can include bacteria, fungi, mycoplasma or spiroplasma, mycobacteria, rickettsia, protozoa, parasites, transmissible spongiform encephalopathy (TSE) agents and viruses.

Note 2 to entry: Adventitious agents are a subset of impurity for *cellular therapeutic product* (3.15).

3.3

analytical method

investigative procedure for qualitatively or quantitatively measuring or assessing the presence, amount, or functional activity of a target entity (the analyte)